REFERENCE
Valentine W, Munro V, Brandt AS, Ray J, Roze S, Foos V, Palmer A.Long-term cost-effectiveness analysis of repaglinide + metformin versus nateglinide + metformin in type 2 diabetes patients with inadequate glycemic control on monotherapy: a Finnish analysis. Value in Health 9: 34, No. 3, May-Jun 2006
Rights and permissions
About this article
Cite this article
In Finland, repaglinide is dominant to nateglinide as combination therapy with metformin for the treatment of type 2 diabetes mellitus inadequately controlled with monotherapy,. Pharmacoecon. Outcomes News 507, 8 (2006). https://doi.org/10.2165/00151234-200605070-00013
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605070-00013